Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holly W Smith

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Immunotoxicology|October 30, 2008
Preclinical immunogenicity testing for recombinant therapeutic proteinsHolly W Smith, Daniel Wierda
The AAPS Journal|March 8, 2011
Summary of confirmation cut point discussionsHolly W Smith, Michael Moxness, Robin Marsden
Regulatory Toxicology and Pharmacology : RTP|September 18, 2007
Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISAHolly W Smith, Anthony Butterfield, Deqin Sun
Journal of Pharmacological and Toxicological Methods|October 1, 2009
Electrochemiluminescent immunoassay for rat skeletal troponin I (Tnni2) in serumDeqin Sun, Diane Hamlin, Anthony Butterfield, et al.
Toxicology|November 26, 2003
A predictive F344 rat immunotoxicology model: cellular parameters combined with humoral response to NP-CgammaG and KLHHolly W Smith, Colleen J Winstead, Kristen K Stank, et al.
Toxicologic Pathology|April 7, 2011
A comparison of mortality and cardiac biomarker response between three outbred stocks of Sprague Dawley rats treated with isoproterenolA Eric Schultze, Bradley W Main, D Greg Hall, et al.
Endocrinology|April 11, 2015
Effects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male MonkeysJohn L Vahle, Richard A Byrd, Jamie L Blackbourne, et al.
Endocrinology|April 11, 2015
Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in RodentsRichard A Byrd, Steven D Sorden, Thomas Ryan, et al.
Toxicologic Pathology|April 30, 2014
Nonclinical safety biomarkers of drug-induced vascular injury: current status and blueprint for the futureIgor Mikaelian, Mark Cameron, Deidre A Dalmas, et al.
Journal of Immunological Methods|February 16, 2008
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology productsEugen Koren, Holly W Smith, Elizabeth Shores, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Immunotoxicology|October 30, 2008
Preclinical immunogenicity testing for recombinant therapeutic proteinsHolly W Smith, Daniel Wierda
The AAPS Journal|March 8, 2011
Summary of confirmation cut point discussionsHolly W Smith, Michael Moxness, Robin Marsden
Regulatory Toxicology and Pharmacology : RTP|September 18, 2007
Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISAHolly W Smith, Anthony Butterfield, Deqin Sun
Journal of Pharmacological and Toxicological Methods|October 1, 2009
Electrochemiluminescent immunoassay for rat skeletal troponin I (Tnni2) in serumDeqin Sun, Diane Hamlin, Anthony Butterfield, et al.
Toxicology|November 26, 2003
A predictive F344 rat immunotoxicology model: cellular parameters combined with humoral response to NP-CgammaG and KLHHolly W Smith, Colleen J Winstead, Kristen K Stank, et al.
Toxicologic Pathology|April 7, 2011
A comparison of mortality and cardiac biomarker response between three outbred stocks of Sprague Dawley rats treated with isoproterenolA Eric Schultze, Bradley W Main, D Greg Hall, et al.
Endocrinology|April 11, 2015
Effects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male MonkeysJohn L Vahle, Richard A Byrd, Jamie L Blackbourne, et al.
Endocrinology|April 11, 2015
Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in RodentsRichard A Byrd, Steven D Sorden, Thomas Ryan, et al.
Toxicologic Pathology|April 30, 2014
Nonclinical safety biomarkers of drug-induced vascular injury: current status and blueprint for the futureIgor Mikaelian, Mark Cameron, Deidre A Dalmas, et al.
Journal of Immunological Methods|February 16, 2008
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology productsEugen Koren, Holly W Smith, Elizabeth Shores, et al.
Pageof 1